Abstract 444P
Background
Cancer care in French Polynesia has been deprioritized during severe acute respiratory syndrome coronavirus 2 (SARS CoV2) pandemic due to the urgent necessity to reorganize health care systems to fight this crisis and patients (pts) were more reluctant to visit medical doctors, fearful about exposure to the virus or not wanting to disturb a saturated health system.
Methods
We aimed to assess the incidence of cancer diagnosis and cancer care during the Covid-19 period compared to the same period in 2019 (before covid) and in 2021 (after covid). We retrospectively collected data from January 2019 to Sept 2021 regarding pts visits, treatments (ttt) administrations in oncology and radiotherapy outpatient wards, at the Taaone university hospital center of French Polynesia.
Results
Regarding the newly diagnosed pts, we observed a decreased of 13.6% on oncology visits from January to Sept 2020 compared to the same period in 2019 and an increase of oncology visits after the first wave with +14.2%, from January to Sept 2021 compared to 2020. We did not observe any major impact of the crisis on ttt administrations in oncology outpatients. There was a +1.3% of activity from January to Sept 2020 compared to 2019 and a +1.5% from January to Sept 2021 compare to 2020. Regarding the radiotherapy activity, the newly diagnosed pts visits increased of +2.5% from January to Sept 2020 compared to the same period in 2019 and +21% from January to Sept 2021 compared to the same period in 2020. The ttts in radiotherapy outpatient wards decreased of -11% in 2020 (from January to Sept 2020 compared to 2019) and increased of +11% in 2021.
Conclusions
The covid 19 crisis had an impact in French Polynesia on the oncology and radiotherapy visit of the newly diagnosed patients, with more patients diagnosed after covid; while ttt administrations in oncology and radiotherapy stayed stable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
451P - The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution
Presenter: Peng Zhang
Session: Poster viewing 06
452P - Medical and paramedical students’ awareness of environmental risk factors for cancer
Presenter: Mostafa Behery
Session: Poster viewing 06
453P - Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia
Presenter: Rico Hutabarat
Session: Poster viewing 06
454P - To study the prevalence of lower limb deep vein thrombosis in patients who present with stage III/IV solid tissue malignancies in Indian patients
Presenter: Oshin Suri
Session: Poster viewing 06
455P - Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India
Presenter: Akhil Santhosh
Session: Poster viewing 06
456P - Outcomes of COVID-19 infection in cancer patients: A single center study
Presenter: Sindhu G
Session: Poster viewing 06
457P - The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta
Presenter: Meirisa Ardianti
Session: Poster viewing 06
458P - A real-world depiction of difficulties in applicability of IO regimens into clinical practice in metastatic setting
Presenter: Sharat Chandra Goteti
Session: Poster viewing 06
460P - The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer
Presenter: Jae-Joon Kim
Session: Poster viewing 06
461P - Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India
Presenter: Nitin Murthy
Session: Poster viewing 06